SCHEMBL20120992

SCHEMBL20120992

O=CCOC1CC(OCc2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.45
▸ CTSB P07858 1/20 0.45
▸ CTSK P43235 1/20 0.45
▸ NAAA Q02083 3/20 0.42
▸ AGTR2 P50052 2/20 0.41
▸ OPRM1 P35372 2/20 0.41
▸ OPRL1 P41146 2/20 0.41
▸ DPP4 P27487 1/20 0.41
▸ SIGMAR1 Q99720 2/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.39
▸ CARM1 Q86X55 1/20 0.39
▸ PRMT6 Q96LA8 1/20 0.39
▸ PRMT8 Q9NR22 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ PDPK1 O15530 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20120990 1.00 CTSL (0.45) CTSLCTSBCTSKNAAAAGTR2
SCHEMBL2650237 0.83 CTSL (0.45) CTSLCTSBCTSKNAAAAGTR2
SCHEMBL20121044 0.83 CTSL (0.45) CTSLCTSBCTSKNAAAOPRM1
SCHEMBL20121045 0.83 CTSL (0.45) CTSLCTSBCTSKNAAAOPRM1
SCHEMBL25383389 0.81 NAAA (0.47) CTSLCTSBCTSKNAAAAGTR2
SCHEMBL26105674 0.81 CTSL (0.46) CTSLCTSBCTSKNAAAAGTR2
SCHEMBL21141929 0.81 CTSL (0.46) CTSLCTSBCTSKNAAAAGTR2
SCHEMBL24899061 0.81 CTSL (0.46) CTSLCTSBCTSKNAAAAGTR2
SCHEMBL871908 0.77 NPC1 (0.49) CTSLCTSBCTSKNAAAAGTR2
SCHEMBL8347290 0.77 NPC1 (0.49) CTSLCTSBCTSKNAAAAGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559486-B2 Tau-protein targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 — — US disclosed
CN-119954801-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-05-09 — — CN disclosed
CN-114867727-B TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-02-21 — — CN disclosed
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-23 — — US disclosed
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-06 — — US disclosed
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use ARVINAS OPERATIONS, INC. (US) 2022-10-04 — — US disclosed
CN-114867727-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2022-08-05 — — CN disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 — — WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 — — WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT CTSL 3340/4885CTSB 2539/4885CTSK 2852/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN CTSL 3582/4885CTSB 2723/4885CTSK 3042/4885
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 CTSL 2961/4885CTSB 2742/4885CTSK 2765/4885
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use CRBN, VHL, UBQLN2 CTSL 2961/4885CTSB 2742/4885CTSK 2765/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 CTSL 2961/4885CTSB 2742/4885CTSK 2765/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT CTSL 3340/4885CTSB 2539/4885CTSK 2852/4885
US-12559486-B2 Tau-protein targeting compounds and associated methods of use UBQLN2, UBQLN1, CRBN CTSL 3380/4885CTSB 3026/4885CTSK 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback